Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05971758 · ClinicalTrials.gov registry record · Phase 2
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
A Phase 2 study of Cushing Disease, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05971758 is a Phase 2 study of Cushing Disease that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 20 participants, below the 390-participant average among 8 other Cushing Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05971758, a Phase 2 study of Cushing Disease, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Supported by the pre-clinical data (summarized in Research Strategy), the investigators propose that Fimepinostat is an ideal candidate drug in the treatment and intervention of patients with Cushing Disease. The investigators propose a pilot, short-term (4 weeks) phase II single-center study to demonstrate the safety and efficacy of Fimepinostat in the treatment of patients with de novo, persistent, and/or recurrent CD recruited at the University of California, Los Angeles. The trial will have a 2-arm design and will simultaneously examine two different doses of Fimepinostat. The study will allow the investigators to determine the efficacy and safety of these doses in the treatment of CD and guide dose selection for subsequent, larger studies. Funding Source - FDA OOPD.
Conditions Studied
Interventions
- DRUG Fimepinostat
Study Locations (1)
California
- Ronald Reagan Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-01-16 |
| Est. Completion | 2029-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05971758
The ClinicalTrials.gov registry entry for NCT05971758 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 390-participant average among 8 other Cushing Disease trials with a reported enrollment target (95% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cushing Disease appearing as the primary indexed condition, and to 1 intervention - of which Fimepinostat is the first listed.
NCT05971758 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05971758 about?
NCT05971758 is a clinical study titled "Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease". Supported by the pre-clinical data (summarized in Research Strategy), the investigators propose that Fimepinostat is an ideal candidate drug in the treatment and intervention of patients with Cushing Disease. The investigators propose a pilot, short-term (4 weeks) phase II single-center study to dem...
What is the current status of trial NCT05971758?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-01-16. Estimated completion is 2029-01.
What conditions does trial NCT05971758 study?
This clinical trial studies the following conditions: Cushing Disease.
What interventions are being tested in trial NCT05971758?
The interventions under investigation include: Fimepinostat (DRUG).
Who is sponsoring clinical trial NCT05971758?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05971758 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cushing Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
RECRUITING · Phase 2
-
Safety and Efficacy of LCI699 in Cushing's Disease Patients
COMPLETED · Phase 2
-
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
RECRUITING
-
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
RECRUITING · Phase 1
-
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
RECRUITING
-
Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.